Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to April 2014

Omega-7 Protects Against Metabolic Syndrome

April 2014

By Carol Stockton

Palmitoleic Acid Improves Arterial Health

Omega-7’s ability to raise HDL and lower LDL—while also supporting endothelial function—make it extremely beneficial for cardiovascular health.

Studies show that omega-7 improves lipid balance by favorably regulating fat production within fat cells, while regulating fat burning.2 That means less fat deposition—and lower levels of fat and triglycerides in blood and liver tissue.3,25

In a lab study done at the Cleveland Clinic, omega-7 supplementation increased beneficial HDL after just 8 to 12 weeks (something statin drugs are not very good at doing).5,26,27 In the same study, the reduction in the size of atherosclerotic plaque in the aorta was 47% lower in the group receiving omega-7 supplementation.5

Omega-7 levels have also been shown to be powerful predictors of the all-important endothelial function, the control of blood flow and pressure by the inner lining, or endothelium, of blood vessels.28

Palmitoleic Acid Improves Arterial Health  

These beneficial effects on cholesterol were demonstrated by a study using macadamia nuts and sea buckthorn, two substances that are known for their high omega-7 content. Studies show that after just three weeks of eating macadamia nuts every day, healthy young women had reductions in total and LDL cholesterol, body weight, and body mass index (BMI).29 And in men with high cholesterol, 1 to 3 ounces per day of these fat-containing nuts produced reductions in atherosclerosis risk factors such as markers of inflammation and oxidative stress.30

These studies may have shown greater effects had the subjects used a purified omega-7 palmitoleic acid supplement instead of the high-fat macadamia nuts, which are also rich in dangerous palmitic acid.

In a study of patients with stubbornly high lipid levels, a purified omega-7 supplement (840 mg/day) produced modest lipid reductions. LDL fell by 7.6% (from 118 to 109 mg/dL) while non-HDL cholesterol* was reduced by 8.2% (from 147 to 135 mg/dL).6 Patients with the highest levels of baseline triglycerides saw their total cholesterol and triglyceride levels drop by as much as 30%.6

* (Non-HDL cholesterol is gaining increasing importance as a risk marker for cardiovascular outcomes.6 It is calculated as total cholesterol minus HDL cholesterol.)

What makes that study remarkable is that most participants were already taking statin or fibrate drugs, yet still had high lipid levels.25 This showed that adding omega-7 to these drugs produced additional benefits, lowering cholesterol and triglycerides where prescription drugs couldn’t.

In a subsequent controlled clinical trial, patients taking purified omega-7 palmitoleic acid at a lower dose (210 mg/day) had improvements in lipid levels after 30 days of supplementation: triglycerides dropped by 36.9 mg/dL (17%), LDL by 13.5 mg/dL (11%), and beneficial HDL rose by 4.5 mg/dL (10%).7

Omega-7 Helps Manage Body Weight

The reason central or abdominal obesity (“apple shape”) is a factor in metabolic syndrome is because it has such strong associations with cardiovascular disease risk.31 This is due, in large part, to the increased inflammation produced by fat tissue.17-19

Omega-7s help manage this factor of metabolic syndrome because they signal your body to stop storing fat.2,3

Animals fed diets rich in omega-7 show significant increases in stomach and intestinal hormones that promote the feeling of fullness (satiety).13 At the same time, such diets produce decreases in hunger-promoting hormones.32 The combined effect is a significant reduction in food intake.

Several statin drugs, while lowering cholesterol and triglycerides, also produce increases in body and liver fat deposition.33 Omega-7s do just the opposite. Omega-7 reduces the production of fat in the liver.3 Increases in liver fat can result in non-alcoholic fatty liver disease (NAFLD), which is considered a major manifestation of the metabolic syndrome—and which can eventually lead to liver failure and even cancer.34


Research has shown that omega-7 has beneficial effects on a majority of the pathological components of metabolic syndrome.

It improves insulin sensitivity, lowers LDL-cholesterol-triglycerides, and raises beneficial HDL.3,5,22,24,29 It helps manage body weight by promoting fullness-inducing hormones and dissipating hunger-producing hormones.13,32 Perhaps most important of all, omega-7 acts in a unique fashion to stop the inflammation that forms the link between the metabolic syndrome and its life-shortening consequences.3,21

By beneficially influencing these deadly pathological factors, omega-7 can dramatically improve cardiovascular and metabolic health.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.


  1. Cao H, Hotamisligil G, Inventors; President and Fellows of Harvard College, Cambridge, MA, assignee. Fatty acid C16: 1N7-Palmitoleate a lipokine and biomarker for metabolic status. September 1, 2011.
  2. Burns TA, Duckett SK, Pratt SL, Jenkins TC. Supplemental palmitoleic (C16:1 cis-9) acid reduces lipogenesis and desaturation in bovine adipocyte cultures. J Anim Sci. 2012 Oct;90(10):3433-41.
  3. Yang ZH, Miyahara H, Hatanaka A. Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis. 2011;10:120.
  4. Stefan N, Kantartzis K, Celebi N, et al. Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care. 2010 Feb;33(2):405-7.
  5. Experimental Animal Laboratory. Final report for study onCCO Technologies Oil (CCO-Oil) on the development of atherosclerosis: Department of Cardiovascular Medicine, Cleveland Clinic; 2008.
  6. Green JA. Effect of two levels of Provinal™ (purified Palmitoleic Acid; C16:1n7; Omega 7) on serum lipid and C-reactive protein(CRP) profiles in humans. Tersus Pharmaceuticals, LLC: 2012.
  7. Martinez L. Provinal (R) in the reduction of CRP: A double blinded, randomized, placebo controlled study. Provinal purified omega 7. Vol: Tersus Pharmaceuticals; 2013.
  8. Marcus AO. Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. Diabetes Technol Ther. 2000 Spring;2(1):101-10.
  9. Available at: Accessed January 24, 2014.
  10. Nestel P, Clifton P, Noakes M. Effects of increasing dietary palmitoleic acid compared with palmitic and oleic acids on plasma lipids of hypercholesterolemic men. J Lipid Res. 1994 Apr;35(4):656-62.
  11. Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002 Aug;61(3):345-58.
  12. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008 Sep 19;134(6):933-44.
  13. Yang ZH, Takeo J, Katayama M. Oral administration of omega-7 palmitoleic acid induces satiety and the release of appetite-related hormones in male rats. Appetite. 2013 Jun;65:1-7.
  14. Burns TA, Kadegowda AK, Duckett SK, Pratt SL, Jenkins TC. Palmitoleic (16:1 cis-9) and cis-vaccenic (18:1 cis-11) acid alter lipogenesis in bovine adipocyte cultures. Lipids. 2012 Dec;47(12):1143-53.
  15. Available at: Accessed January 24, 2014.
  16. Available at: Accessed January 8, 2014.
  17. Available at: Accessed January 8, 2014.
  18. Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000 Jul 4;102(1):42-7.
  19. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):638-44.
  20. Liu X, Miyazaki M, Flowers MT, et al. Loss of Stearoyl-CoA desaturase-1 attenuates adipocyte inflammation: effects of adipocyte-derived oleate. Arterioscler Thromb Vasc Biol. 2010 Jan;30(1):31-8.
  21. Guo X, Li H, Xu H, et al. Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS One. 2012;7(6):e39286.
  22. Dimopoulos N, Watson M, Sakamoto K, Hundal HS. Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J. 2006 Nov 1;399(3):473-81.
  23. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006 Jul;116(7):1802-12.
  24. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes. 2001 Jan;50(1):69-76.
  25. Shiba S, Tsunoda N, Wakutsu M, et al. Regulation of lipid metabolism by palmitoleate and eicosapentaenoic acid (EPA) in mice fed a high-fat diet. Biosci Biotechnol Biochem. 2011;75(12):2401-3.
  26. Chang YH, Lin KC, Chang DM, Hsieh CH, Lee YJ. Paradoxical negative HDL cholesterol response to Atorvastatin and Simvastatin treatment in Chinese type 2 diabetic patients. Rev Diabet Stud. 2013 Summer;10(2-3):213-22.
  27. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis. 2002 Oct;164(2):361-9.
  28. Sarabi M, Vessby B, Millgard J, Lind L. Endothelium-dependent vasodilation is related to the fatty acid composition of serum lipids in healthy subjects. Atherosclerosis. 2001 Jun;156(2):349-55.
  29. Hiraoka-Yamamoto J, Ikeda K, Negishi H, et al. Serum lipid effects of a monounsaturated (palmitoleic) fatty acid-rich diet based on macadamia nuts in healthy, young Japanese women. Clin Exp Pharmacol Physiol. 2004 Dec;31 Suppl 2:S37-8.
  30. Garg ML, Blake RJ, Wills RB, Clayton EH. Macadamia nut consumption modulates favourably risk factors for coronary artery disease in hypercholesterolemic subjects. Lipids. 2007 Jun;42(6):583-7.
  31. Elbassuoni E. Better association of waist circumference with insulin resistance and some cardiovascular risk factors than body mass index. Endocr Regul. 2013 Jan;47(1):3-14.
  32. Lu X, Zhao X, Feng J, et al. Postprandial inhibition of gastric ghrelin secretion by long-chain fatty acid through GPR120 in isolated gastric ghrelin cells and mice. Am J Physiol Gastrointest Liver Physiol. 2012 Aug 1;303(3):G367-76.
  33. Aguirre L, Hijona E, Macarulla MT, et al. Several statins increase body and liver fat accumulation in a model of metabolic syndrome. J Physiol Pharmacol. 2013 Jun;64(3):281-8.
  34. Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Non-alcoholic fatty liver disease: a diabetologist’s perspective. Endocrine. 2013 Nov 28.
  35. Cignarelli A, Giorgino F, Vettor R. Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. Arch Physiol Biochem. 2013 Oct;119(4):139-50.
  36. Dzien A, Winner H, Theurl E, Dzien-Bischinger C, Lechleitner M. Fat-free mass and fasting glucose values in patients with and without statin therapy assigned to age groups between <60 and >75 years. Obes Facts. 2013;6(1):9-16.
  37. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol. 2003 Aug 18;92(4a):50j-60j.
  38. Greque GV, Serrano CV, Jr., Strunz CM, et al. Preprocedural statin therapy, inflammation and myocardial injury in low-risk stable coronary artery disease patients submitted to coronary stent implantation. Catheter Cardiovasc Interv. 2013 Apr 16.
  39. Larsen PJ, Jensen PB, Sorensen RV, et al. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes. 2003 Sep;52(9):2249-59.
  40. Oh TJ, Shin JY, Kang GH, Park KS, Cho YM. Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats. Exp Mol Med. 2013;45:e30.
  41. Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):393-9.
  42. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-42.
  43. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125.
  44. Wang W, Lin Q, Lin R, et al. PPARalpha agonist fenofibrate attenuates TNF-alpha-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res. 2013 Jun 10;319(10):1523-33.
  45. Yoon JS, Lee HW. Diabetogenic effect of statins: A double-edged sword? Diabetes Metab J. 2013 Dec;37(6):415-22.
  46. Brindisi MC, Guiu B, Duvillard L, et al. Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes. Atherosclerosis. 2012 Oct;224(2):465-8.
  47. Available at: Accessed January 13, 2014.
  48. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012 Sep;29(9):736-46.
  49. Celinski K, Dworzanski T, Fornal R, et al. Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. J Physiol Pharmacol. 2013 Oct;64(5):587-95.
  50. Petrazzi L, Grassi D, Polidoro L, et al. Cardiovascular risk and cardiometabolic protection: role of glitazones. J Nephrol. 2008 Nov-Dec;21(6):826-35.
  51. Available at: Accessed January 13, 2014.
  52. Cefalu JT, Bell-Farrow A, Wang ZQ, McBride D, Dalgleish D, Terry JG. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. Drug Dev Res.1998 May;44(1):1-7.
  53. Available at: Accessed January 13, 2014.
  54. Available at: Accessed January 13, 2014.
  55. Connor WE. Harbingers of coronary heart disease: dietary saturated fatty acids and cholesterol. Is chocolate benign because of its stearic acid content? Am J Clin Nutr. 1999 Dec;70(6):951-2.
  56. Mizurini DM, Maia IC, Sardinha FL, Monteiro RQ, Ortiz-Costa S, do Carmo MG. Venous thrombosis risk: effects of palm oil and hydrogenated fat diet in rats. Nutrition. 2011 Feb;27(2):233-8.
  57. Anderson SG, Sanders TA, Cruickshank JK. Plasma fatty acid composition as a predictor of arterial stiffness and mortality. Hypertension. 2009 May;53(5):839-45
  58. Yang B, Kallio HP. Fatty acid composition of lipids in sea buckthorn (Hippophaë rhamnoides L.) berries of different origins. J Agric Food Chem. 2001 Apr;49(4):1939-47.
  59. Corporate data on file. Fatty acid profile: Tersus Pharmaceutical; 2013.